Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 25, 2010Molecular Cancer Therapeutics

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

View Full Paper
Ask AI
Bookmark
Share

Authors

NONeil A. O’BrienAPLA HealthBBBrigid C. BrowneGarvan Institute of Medical ResearchLCLucy ChowUniversity of California, Los Angeles

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

O’Brien et al. (2010) studied this question.

synapsesocial.com/papers/6a08faee0465d979db9d0a75https://doi.org/10.1158/1535-7163.mct-09-1171
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ2352008 · 499 citations
  2. 2Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene1987 · 11,843 citations
  3. 3Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy2008 · 195 citations
  4. 4A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer2006 · 379 citations
  5. 5Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer2002 · 2,949 citations